ArticleCurrent oncology (Toronto, Ont.)2013
Canadian trends in liver cancer: a brief clinical and epidemiologic overview.
Article in Current oncology (Toronto, Ont.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04745390 (A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT In Primary or Secondary Liver Carcinoma (SAVIOR).
Who cites it
8 citing papers in PubMed.
- Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- Stigmatization of drinking patients with liver cancer: The role of socioeconomic status.Heliyon · 2024Article
- Article
- Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.PloS one · 2022Article
- Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.Cancer medicine · 2020Article
- Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases.BMJ open · 2019Observational
- Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007.Cancer causes & control : CCC · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although primary liver cancer is rare, its incidence rate has been rising quickly in Canada, more than tripling since the early 1980s. This cancer is more common in men than women, and the age-specific incidence rates in men have been increasing significantly in all age groups from 40 years of age onward. The death rate has followed a similar upward trajectory, in part because of the low 5-year survival rate of 18% in both sexes. Infection with the hepatitis B or C virus continues to be the most common risk factor, but other factors may also play a role. Risk reduction strategies, such as viral hepatitis screening, have been recommended in other countries and warrant consideration in Canada as part of a coordinated strategy of disease prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.